Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Liabilities: 2015-2023

Historic Total Liabilities for Aytu Biopharma (AYTU) over the last 9 years, with Sep 2023 value amounting to $100.7 million.

  • Aytu Biopharma's Total Liabilities fell 0.92% to $100.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $100.7 million, marking a year-over-year decrease of 0.92%. This contributed to the annual value of $97.1 million for FY2023, which is 4.06% up from last year.
  • Per Aytu Biopharma's latest filing, its Total Liabilities stood at $100.7 million for Q3 2023, which was up 3.72% from $97.1 million recorded in Q2 2023.
  • Aytu Biopharma's 5-year Total Liabilities high stood at $128.4 million for Q1 2021, and its period low was $22.3 million during Q1 2019.
  • In the last 3 years, Aytu Biopharma's Total Liabilities had a median value of $106.3 million in 2023 and averaged $108.5 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 265.39% in 2019, then declined by 27.15% in 2022.
  • Aytu Biopharma's Total Liabilities (Quarterly) stood at $57.4 million in 2019, then fell by 5.82% to $54.0 million in 2020, then surged by 118.85% to $118.3 million in 2021, then declined by 19.16% to $95.6 million in 2022, then dropped by 0.92% to $100.7 million in 2023.
  • Its Total Liabilities was $100.7 million in Q3 2023, compared to $97.1 million in Q2 2023 and $106.3 million in Q1 2023.